The National Cancer Institute Clinical Trials Planning Meeting to Address Gaps in Observational and Intervention Trials for Cancer-Related Cognitive Impairment

By sjmartinez • September 10, 2024

Janelsins MC, Van Dyk K, Hartman SJ, Koll TT, Cramer CK, Lesser GJ, Barton DL, Mustian KM, Wagner LI, Ganz PA, Cole PD, Bakos A, Root JC, Hardy K, Magnuson A, Ferguson RJ, McDonald BC, Saykin AJ, Gonzalez BD, Wefel JS, Morilak DA, Dahiya S, Heijnen CJ, Conley YP, Morgans AK, Mabbott D, Monje M, Rapp SR, Gondi V, Bender C, Embry L, McCaskill Stevens W, Hopkins JO, St Germain D, Dorsey SG. The National Cancer Institute Clinical Trials Planning Meeting to Address Gaps in Observational and Intervention Trials for Cancer-Related Cognitive Impairment. J Natl Cancer Inst. 2024 Sep 9:djae209. doi: 10.1093/jnci/djae209. Epub ahead of print. PMID: 39250738.

Tags: Hematology/Oncology, Publications

Related Posts

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Hwang S, Shin DJ, Kang B, Kang H, Lee SH, Kim JS, Joung JG, Jain S, Olsen S, Becker L, Finn RS, Llovet JM, Kim[...]

KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy

Rugo HS, Cescon DW, Robson ME, Im SA, Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk S, Dudnichenko O, Llinás-Quintero N,[...]

Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical Trial

Nikitas J, Kendal JK, Savjani RR, Jackson N, Peterson N, Deng J, Hernandez J, Chong N, Singh AS, Chmielowski B, Federman NC, Crompton JG, Kadera[...]